Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Apellis Pharmaceuticals (APLS) Leases (2020 - 2025)

Apellis Pharmaceuticals has reported Leases over the past 6 years, most recently at $18.2 million for Q4 2025.

  • Quarterly results put Leases at $18.2 million for Q4 2025, up 13.13% from a year ago — trailing twelve months through Dec 2025 was $18.2 million (up 13.13% YoY), and the annual figure for FY2025 was $18.2 million, up 13.13%.
  • Leases for Q4 2025 was $18.2 million at Apellis Pharmaceuticals, down from $19.7 million in the prior quarter.
  • Over the last five years, Leases for APLS hit a ceiling of $22.5 million in Q1 2021 and a floor of $14.6 million in Q2 2025.
  • Median Leases over the past 5 years was $18.0 million (2023), compared with a mean of $18.2 million.
  • Biggest five-year swings in Leases: skyrocketed 69.3% in 2021 and later dropped 20.68% in 2023.
  • Apellis Pharmaceuticals' Leases stood at $19.9 million in 2021, then fell by 5.8% to $18.7 million in 2022, then dropped by 10.68% to $16.7 million in 2023, then dropped by 3.95% to $16.1 million in 2024, then rose by 13.13% to $18.2 million in 2025.
  • The last three reported values for Leases were $18.2 million (Q4 2025), $19.7 million (Q3 2025), and $14.6 million (Q2 2025) per Business Quant data.